Covance Doubles Service Capacity and Expertise for Metabolite Identification
To conduct metabolite identification supporting preclinical development and early human studies, Covance Inc. has announced a substantial increase in global capacity and expertise. The expansion increases Covance’s global scientific staff and equipment supporting metabolite identification to enable clients to start studies sooner and obtain results faster.
Covance’s global scientific staff dedicated to metabolite identification studies now includes 14 senior scientists located in Madison, Wisconsin and Harrogate, United Kingdom. New equipment brings the total instrumentation to five accurate mass Spectrometers, six QTrap mass spectrometers and access to nuclear magnetic resonance (NMR) analysis for unequivocal structural identification.
The additions at the Madison facility will better accommodate increased client demand resulting from the Food and Drug Administration’s (FDA) recent Guidance for Industry on Safety Testing of Drug Metabolites. The Guidance recommends when and how to identify and characterize drug metabolites whose nonclinical toxicity needs evaluation.
Covance has conducted hundreds of metabolite identification studies to date in Madison, Wisconsin and Harrogate, UK. Globally, Covance provides comprehensive drug metabolism services to pharmaceutical companies and hundreds of smaller pharmaceutical and biotech companies.
About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.7 billion, global operations in more than 25 countries, and more than 9,800 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
